Cancer cell amino acid uptake and protein synthesis machinery

The cancer cell amino acid uptake and protein synthesis machinery represents a coordinated network of transporters and signaling pathways that support the high metabolic demands of malignant cells. Central to this system are amino acid transporters such as L-type amino acid transporter 1 (LAT1/SLC7A5) and Alanine-serine-cysteine transporter 2 (ASCT2/SLC1A5), which facilitate the influx of essential nutrients like leucine and glutamine (Kandasamy et al., 2021, Journal of Biological Chemistry). Once inside the cell, these amino acids activate the Mechanistic Target of Rapamycin Complex 1 (mTORC1), a master regulator that integrates nutrient sensing with the protein synthesis apparatus (Saxton & Sabatini, 2017, Cell). The machinery also includes the translation initiation complex (eIF4F) and ribosomes, which execute the assembly of new proteins required for cell division and survival. Pharmacological intervention often targets specific nodes within this system, such as mTOR inhibitors (e.g., Everolimus) or direct inhibitors of translation (e.g., Omacetaxine mepesuccinate) (Gandhi et al., 2014, Clinical Cancer Research). However, because these processes are also vital for normal high-turnover tissues, therapeutic windows can be narrow, leading to side effects like immunosuppression and mucosal inflammation.

Other names

Amino acid transport and protein translation pathwayCancer nutrient uptake machinerymTOR-regulated protein synthesis pathwayCancer metabolic reprogramming of protein synthesis

Inhibition of amino acid transporters (e.g., LAT1, ASCT2), inhibition of the mTORC1 signaling complex, or direct interference with ribosomal protein synthesis.